Boundless Bio, Inc.
BOLD
NASDAQ·Healthcare·Biotechnology·Mkt cap $65.0M
$2.90
▲ +0.35%
P/E
-1.01
Mkt Cap
$65.0M
52-Wk Range
$0.96–$3.16
52-Week Range
$0.96 - $3.16
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 151.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary ecDNA-targeting platform technology
- First-mover advantage in oncogene amplification treatment
- Experienced oncology and precision medicine team
- Novel mechanism of action addressing resistance gene amplifications
Bear Case
1 risk
- Low volatility (beta 0.4).
Growth
Stable outlook
Advancement of BBI-355 and BBI-825 through clinical trial phases
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+102.1% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying BOLD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 7, 2026
Reported EPS of -$1.06 vs -$1.06 consensus (0.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
0.0%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
0%
Sell
100%
Median Price Target
—
Latest: UBS · Jun 23, 2026
vs Industry
How BOLD stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related